Nov 08, 2019
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Nov 04, 2019
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
Oct 30, 2019
Global Schizophrenia Drugs (Orals & Injectables) Market Insights, Trends and Forecasts, 2013-2018 & 2019-2023
Oct 21, 2019
Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
Oct 16, 2019
Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results
Sep 26, 2019
Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference
Sep 24, 2019
Outlook on the Sustained Release Injectables Market to 2026 - Featuring Eli Lilly, AstraZeneca, Ipsen, Novartis, Roche, Sanofi, and More
Sep 13, 2019
Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.
Jul 29, 2019
Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
Jul 25, 2019
Alkermes Plc Reports Second Quarter 2019 Financial Results
Jul 18, 2019
Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results
Jul 15, 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Jul 01, 2019
Alkermes Demonstrates Commitment to Local Community for 11th Consecutive Year With Largest Volunteer Event in Company History
Apr 25, 2019
Alkermes Plc Reports First Quarter 2019 Financial Results
Apr 18, 2019
Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results
Apr 09, 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia
Apr 08, 2019
Alkermes Announces Departure of Jim Robinson
Apr 03, 2019
Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia
Apr 01, 2019
Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society
Feb 26, 2019
Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors